Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.53 |
| ▸ | ARG2 | P78540 | 1/20 | 0.53 |
| ▸ | ACLY | P53396 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.47 |
| ▸ | GGT1 | P19440 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CPT2 | P23786 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1975908 | 1.00 | ARG1 (0.53) | ARG1ARG2ACLYMAPTABCC4 | |
| SCHEMBL22862319 | 1.00 | ARG1 (0.53) | ARG1ARG2ACLYMAPTABCC4 | |
| SCHEMBL19305278 | 1.00 | ARG1 (0.53) | ARG1ARG2ACLYMAPTABCC4 | |
| SCHEMBL19357334 | 1.00 | ARG1 (0.53) | ARG1ARG2ACLYMAPTABCC4 | |
| SCHEMBL1975910 | 1.00 | ARG1 (0.53) | ARG1ARG2ACLYMAPTABCC4 | |
| SCHEMBL18954854 | 1.00 | ARG1 (0.53) | ARG1ARG2ACLYMAPTABCC4 | |
| SCHEMBL18954850 | 1.00 | ARG1 (0.53) | ARG1ARG2ACLYMAPTABCC4 | |
| SCHEMBL16401653 | 0.98 | ARG1 (0.55) | ARG1ARG2ACLYMAPTABCC4 | |
| SCHEMBL18954910 | 0.98 | ARG1 (0.55) | ARG1ARG2ACLYMAPTABCC4 | |
| SCHEMBL19305277 | 0.98 | ARG1 (0.55) | ARG1ARG2ACLYMAPTABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-05-26 | — | — | US | claimed |
| WO-2025245225-A1 | STAPLED PEPTIDE PROTEOLYSIS TARGETING CHIMERAS (SP-PROTACS) AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| EP-3986438-B1 | P53 ACTIVATOR PEPTIDOMIMETIC MACROCYCLES | MERCK SHARP & DOHME LLC (US) | 2025-04-16 | — | — | EP | claimed |
| US-12264185-B2 | Stabilized BCL9 peptides for treatment of aberrant Wnt signaling | WNTRX PHARMACEUTICALS INC. (US) | 2025-04-01 | — | — | US | claimed |
| US-20250034211-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | MERCK SHARP & DOHME LLC (US) | 2025-01-30 | — | — | US | claimed |
| US-20240343765-A1 | STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION | DANA-FARBER CANCER INSTITUTE, INC. | 2024-10-17 | — | — | US | claimed |
| EP-4441067-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | Merck Sharp & Dohme LLC (US) | 2024-10-09 | — | — | EP | claimed |
| US-20240317826-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR IDENTIFYING AN AGENT FOR TREATING HIV-1 INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-26 | — | — | US | claimed |
| US-20240317803-A1 | BCL9 PEPTIDES AND VARIANTS THEREOF | WNTRX PHARMACEUTICALS INC. | 2024-09-26 | — | — | US | claimed |
| EP-3359180-B1 | STABILIZED BCL9 PEPTIDES FOR TREATMENT OF ABERRANT WNT SIGNALING | WNTRX PHARMACEUTICALS INC (US) | 2024-05-15 | — | — | EP | claimed |
| US-20180030090-A1 | NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-01 | — | — | US | claimed |
| EP-3256484-A1 | NON-MEMBRANE DISRUPTIVE p53 ACTIVATING STAPLED PEPTIDES | Agency For Science, Technology And Research (SG) | 2017-12-20 | — | — | EP | claimed |
| WO-2017062518-A1 | STABILIZED BCL9 PEPTIDES FOR TREATMENT OF ABERRANT WNT SIGNALING | WNTRX PHARMACEUTICALS INC. (US) | 2017-04-13 | — | — | WO | claimed |
| WO-2016130092-A1 | NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-08-18 | — | — | WO | claimed |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-02-18 | — | — | US | claimed |
| EP-2976354-A1 | STAPLING eIF4E INTERACTING PEPTIDES | Agency For Science, Technology And Research (SG) | 2016-01-27 | — | — | EP | claimed |
| US-20150291682-A1 | MIMETIC PEPTIDES | LES HOPITAUX UNIVERSITAIRES DE GENEVE (CH) | 2015-10-15 | — | — | US | claimed |
| EP-2917234-A1 | MIMETIC PEPTIDES | Les Hôpitaux Universitaires de Genève (CH) | 2015-09-16 | — | — | EP | claimed |
| WO-2014149001-A1 | STAPLING eIF4E INTERACTING PEPTIDES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-09-25 | — | — | WO | claimed |
| WO-2014072916-A1 | MIMETIC PEPTIDES | LES HOPITAUX UNIVERSITAIRES DE GENEVE (CH) | 2014-05-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317803-A1 | BCL9 PEPTIDES AND VARIANTS THEREOF | BCL9, BCL9L, BCL3 | ARG1 4587/4885ARG2 2348/4885ACLY 4169/4885 |
| US-20180030090-A1 | NON-MEMBRANE DISRUPTIVE P53 ACTIVATING STAPLED PEPTIDES | TP53, ANXA3, ANXA2 | ARG1 2656/4885ARG2 1202/4885ACLY 1871/4885 |
| US-20240343765-A1 | STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION | VIP, SPPL2B, HM13 | ARG1 329/4885ARG2 293/4885ACLY 3331/4885 |
| US-20160046672-A1 | STAPLING eIF4E INTERACTING PEPTIDES | EIF4EBP1, EIF4E, EIF4G2 | ARG1 3514/4885ARG2 3182/4885ACLY 3448/4885 |
| US-20250034211-A1 | C-TERMINAL EXTENDED P53 ACTIVATOR CROSSLINKED PEPTIDOMIMETIC MACROCYCLES AGAINST MDM2/MDMX | TP53, MDM4, MDM2 | ARG1 986/4885ARG2 901/4885ACLY 954/4885 |
| US-12637492-B2 | Peptide inhibitors of focal adhesion kinase activity and uses thereof | PTK2, ILK, FPR2 | ARG1 2817/4885ARG2 2000/4885ACLY 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.